Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

istration of Excellarate, and a 50% relative improvement was observed as an average over the first four weeks. The Company plans to schedule a meeting with the FDA in early 2010 to review the complete integrated data set and outline plans for a Phase 3 clinical study program designed to confirm the safety and effectiveness of Excellarate as compared to standard of care, since PDGF-B is known to contribute to the biologic process of wound healing and is itself an approved protein product for use in advanced wound care. The Company believes that the combination of collagen and PDGF-B as provided by the Excellarate product candidate holds the potential to further promote wound healing in non-healing diabetic foot ulcers and other difficult-to-treat wounds.

Plans for Commercial Development of Excellagen(TM)

The Company plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate. ExcellagenXL is an advanced wound care device composed of highly-refined, soluble bovine dermal collagen (Type I), which is modified to reduce immunogenicity and promote its usefulness in wound settings. ExcellagenXL is designed for use by physicians in patients with topical wounds, which include diabetic ulcers as well as pressure ulcers, venous ulcers, surgical and trauma wounds, second degree burns, and other types of wounds. The Company expects to submit its FDA 510(k) application for ExcellagenXL during fourth quarter 2009. The planned 510(k) filing is based in part on positive findings from the Company's Phase 2b Matrix clinical study, reported October 14, 2009, indicating that substantial improvements in wound healing responses were observed in patients with non-healing diabetic foot ulcers following one or two applications of ExcellagenXL. The ExcellagenXL topical gel wound care product is designe
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Wilmington, DE (PRWEB) June 18, 2013 ... teachers to the 11th annual DuPont National AgriScience Teachers ... Chesapeake Farms in Chestertown, Md. , ... sponsored by DuPont and is a special project of ... National Association of Agricultural Educators (NAAE) . The ...
(Date:6/18/2013)... 2013 Edison Investment ... announces the initiation of full coverage of ... developing and marketing products for orphan oncology ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has ... investment merits of BioAlliance Pharma, focusing in ...
(Date:6/18/2013)... 18, 2013 This webinar will ... advertising and promotion, and review the basic FDA ... how to apply these principles through real world ... ,     The fundamentals on FDA regulations and guidance ... ,     Assessing traditional and newer forms of ...
(Date:6/18/2013)... June 18, 2013 ... ) has announced the addition of ... & Stable Isotopes Market [SPECT/PET Radioisotopes ... Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, ... report to their offering. ...
Breaking Biology Technology:DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3
... Newly published data by Dr. J.,Barthelow Classen shows ... children with a strong family history of insulin ... diabetes in,vaccine recipients at a rate which exceeds ... vaccines are particularly toxic to those,with a strong ...
... and COLUMBIA, S.C., Feb. 24 ,CareEvolution, Inc. ... & Statistics,are pleased to announce that the ... named a finalist in the Interoperability category ... (MS-HUG) 2008 Innovation,Awards Program. The MS-HUG Healthcare ...
... Feb. 22 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, ... Conference Call, ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... at the ...
Cached Biology Technology:CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 2CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 3
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further ... gastroenterology with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes ... "In its third year, this competition continues to grow ... promising careers in basic and clinical research," said Nicholas ... Foundation. "We are extremely proud of all that these ...
(Date:6/16/2013)... India reduce rates of syphilis, HIV and other sexually ... found. , About two million Indians are ... Andhra Pradesh, Karnataka, Maharashtra and Tamil Nadu. The study, ... Dalla Lana School of Public Health and St. Michael,s ... impact of prevention among female sex workers whose contact ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... Ph.D., Assistant Adjunct Professor, Department of Medicine, University of ... Society for Microbiology (ASM) to receive a 2010 ICAAC ... Division, this award recognizes an early career scientist for ... Diep earned his B.A. in 2000 and his Ph.D. ...
... the "deathstalker" scorpion could help gene therapy become an effective ... therapeutic genes genes that treat disease to reach ... study in ACS Nano , a monthly journal. ... delivery of therapeutic genes into diseased cells shows promise ...
... a substance to enhance the visibility of skin cancer cells ... ultrasound and light. The hybrid scanner could enable doctors to ... its earliest and most curable stages, the report in the ... Younan Xia, and colleagues point out that early diagnosis is ...
Cached Biology News:
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
... Signets FAST RED Chromogen System consists of ... RED reacts in the presence of alkaline ... background noise. The FAST RED System ... ,The System Contains: , , Vial A: ...
The BioLogic Maximizer mixer is for use with the Maximizer valve system. The mixer improves gradient quality by mixing the output of the BioLogic DuoFlow workstation pumps....
... effectively in tubes and 96 well plates. microCLEAN ... one and a half spin DNA cleanup reagent. ... concentrate any type of double stranded DNA, efficiently ... dNTPs (labelled or unlabelled). It is therefore ideally ...
Biology Products: